Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein ( GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback